-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The FDA approved Eli Lilly's once-weekly dual GIP and GLP-1 receptor agonist Mounjaro (tirzepatide) to improve glycemic control in adults with type 2 diabet.
Three different doses of treatment were evaluated in the Phase III SURPASS program involving more than 20,000 patients with type 2 diabetes in 10 clinical trials, five of which were global registry studi.
On average, patients randomized to receive Mounjaro 15mg (the maximum recommended dose) successfully reduced their HbA1c levels by 6% when used alone and by 5% compared to placebo when used with the long-acting dr.
Mounjaro is also being evaluated in six clinical trials for the treatment of obesi.
Eli Lilly recently reported results from the SURMOUNT-1 study, showing that the drug helped patients without type 2 diabetes lose up to 25% of their body weig.
Original source:
Original source:https://firstwordphar.
https://firstwordphar.
com/story/5571833Leave a comment here